AbbVie Inc.ABBV
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NYSE · United States · abbvie.com
AbbVie Inc. is a research-based global biopharmaceutical company focused on developing therapies for serious and complex diseases. Their portfolio includes Humira, Skyrizi, and Rinvoq (immunology), Botox (aesthetics and therapeutics), Venclexta (oncology), and treatments in neuroscience and eye care. AbbVie was spun off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois.
Key ratios
Operating cash flow growth
1.2%TTM
2025
1.2%2024
-17.7%2023
-8.4%
EPS growth
68.5%TTM
2025
-1.3%2024
-12.1%2023
-59.0%
FCF / Sales
28.3%TTM
2025
29.1%2024
31.7%2023
40.6%
Net margin
9.8%TTM
2025
6.9%2024
7.6%2023
9.0%
ROA
10.5%TTM
2025
9.8%2024
8.1%2023
8.3%
ROE
6225.0%TTM
2025
6225.0%2024
62.3%2023
35.2%
Revenue growth
10.4%TTM
2025
8.6%2024
3.7%2023
-6.4%
Recent news
AbbVie TEMPLE Study Demonstrates Superior Tolerability and Efficacy of Atogepant (QULIPTA®) in Head-to-Head Migraine Prevention Trial
Health Canada Approves SKYRIZI® (risankizumab) for Children Living with Moderate to Severe Plaque Psoriasis
EPKINLY® receives Health Canada Approval for Adults with Follicular Lymphoma
AbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum
UBRELVY (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency for Acute Migraine Treatment
AbbVie to Host Second-Quarter 2026 Earnings Conference Call
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
Track ABBV in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer